Brain neurosteroid changes after paroxetine administration in mice

European Neuropsychopharmacology

Volumn 13, Issue 5, 2003, Pages 327-332

  Nechmad, Allon ^a,b   Maayan, Rachel ^a   Spivak, Baruch ^a,c   Ramadan, Edward ^d   Poyurovsky, Michael ^e   Weizman, Abraham ^a,f  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHALVATA MENTAL HEALTH CENTER   (Israel)

^c NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

5 KWD; Allopregnanolone; Anxiety; Depression; Dihydroprogesterone; Neurosteroids; Paroxetine

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 5ALPHA PREGNANE 3,20 DIONE; NEUROSTEROID; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; DRUG EFFICACY; HYPOTHALAMUS; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGESTERONE SYNTHESIS; TRANQUILIZING ACTIVITY;

EID: 0042884347     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00015-4     Document Type: Article

References (23)

1. Altar C.A. Neurotrophins and depression. Trends Pharmacol. Sci. 2:1999;59-61.
2. Baulieu E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology. 23:1998;963-987.
3. Bernardi F., Lanzone A., Cento R.M., Spada R.S., Pezzani I., Genazzani A.D., Luisi S., Luisi M., Petraglia F., Genazzani A.R. Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia. Eur. J. Endocrinol. 142:2000;466-471.
4. Bicikova M., Dibbelt L., Hill M., Hampl R., Starka L. Allopregnanolone in women with premenstrual syndrome. Horm. Metab. Res. 30:1998;227-230.
5. Budziszewska B., Siwanowicz J., Leskiewicz M., Jaworska-Feil L., Lason W. Protective effects of neurosteroids against NMDA-induced seizures and lethality in mice. Eur. Neuropsychopharmacol. 8:1998;7-12.
6. Dong E., Matsumoto K., Uzunova V.V., Sugaya I.I., Takahata H., Nomura H., Watanabe H., Costa E., Guidotti A. Brain 5-alpha-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. USA. 85:2001;2849-2854.
7. Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA. 96:1999;13512-13517.
8. Guidotti A., Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol. Psychiatry. 44:1998;865-873.
9. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 74:1997;299-316.
10. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38:1992;379-395.
11. Melcangi R.C., Cavarretta I., Magnaghi V., Ballabio M., Martini L., Motta M. Crosstalk between normal and tumoral brain cells. Endocrine. 8:1998;65-71.
12. Mensah-Nyagan A.G., Do-Rego D.-L., Beaujeau D., Van L.-T., Pelletier G., Vaudy H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Parmacol. Rev. 51:1999;63-82.
13. Pinna G., Uzunoca V., Matsumoto K., Puia G., Mienville J.M., Costa E., Guidotii A. A brain allopregnanolone regulates the potency of the GABA(A) receptor agonist muscimol. Neuropharmacology. 39:2000;440-448.
14. Purdy R.H., Morrow A.L., Moore P.H. Jr., Paul S.M. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. USA. 88:1991;4553-4557.
15. Romeo E., Strohle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry. 155:1998;910-913.
16. Sanacora G., Mason G.F., Rothman D.L., Behar K.L., Hyder F., Petroff O.A., Berman R.M., Charney D.S., Krystal J.H. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 56:1999;1043-1047.
17. Schatzberg A.F. New indications for antidepressants. J. Clin. Psychiatry. 61:(Suppl. 11):2000;9-17.
18. A-antagonistic neurosteroids in patients with a combat-related post-traumatic stress disorder. Psychol. Med. 20:2000;1227-1231.
19. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 51:1998;215-235.
20. Stewart C.A., Reid I.C. Repeated ECS and fluoxetine administration have equivalent effect on hippocampal synaptic plasticity. Psychopharmacology (Berl.). 148:2000;217-223.
21. Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. USA. 93:1996;12599-12604.
22. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA. 95:1998;3239-3244.
23. Wieland S., Belluzzi J., Hawkinson J.E., Hogenkamp D., Upasani R., Stein L., Wood P.L., Gee K.W., Lan N.C. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology (Berl.). 134:1997;46-54.